Atlas Trials

The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

Clinical trial NCT00526968 · COMPLETED

Trial details

NCT number
NCT00526968
Sponsor
Evotec Neurosciences GmbH
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Human Volunteers
Start date
2007-09-01
Primary completion
2007-12-01
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.